News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 5, 2024

Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

Author(s)Kirollos S. Hanna, PharmD, BCPS, BCOP, Hope Rugo, MD, Joyce O’Shaughnessy, MD

Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.

Episodes in this series

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 3 Outcomes from NATALEE and MonarchE

EP. 3 Outcomes from NATALEE and MonarchE

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

A panel of 4 experts on breast cancer

EP. 5 Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

A panel of 4 experts on breast cancer

EP. 6 Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

A panel of 4 experts on breast cancer

EP. 7 Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

A panel of 4 experts on breast cancer

EP. 8 Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

A panel of 4 experts on breast cancer

EP. 9 Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 10 How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

A panel of 4 experts on breast cancer

EP. 11 Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 12 Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

A panel of 4 experts on breast cancer

EP. 13 ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

What is the potential role of value-based pricing models or alternative payment arrangements in improving access to CDK4/6 inhibitors for eligible patients?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Housing inequity | Image credit: Pix_Std - stock.adobe.com

Historical Redlining Linked to Lower Breast Cancer Screening

ByPearl Steinzor

September 2nd 2026

Adaptive Trials Cut Time to Effective Breast Cancer Therapies: Laura Esserman, MD, MBA

ByGiuliana Grossi,Laura Esserman, MD, MBA,

August 18th 2026

Tiffany Meng, PharmD

ADCs and Oral SERDs Reshape Breast Cancer Pharmacy Role: Tiffany Meng, PharmD

ByGiuliana Grossi,Tiffany Meng, PharmD

August 18th 2026

Lidia Schapira, MD

Adapting Breast Cancer Therapy to the Individual, Not Just the Scan: Lidia Schapira, MD

ByGiuliana Grossi,Lidia Schapira, MD, FASCO

August 14th 2026

Multidisciplinary Geriatric Oncology Improves Breast Cancer Care: Enrique Soto Perez de Celis, MD

BySabrina McCrear,Enrique Soto Perez de Celis, MD, PhD

July 29th 2026

Trending on AJMC

Multiagonists Outpace Older GLP-1 Drugs for Weight Loss

How Long-Acting Injectables Are Changing HIV Care

Less-Intensive Leukemia Regimen Outperforms Standard Chemo

Inside Myeloma’s Evolution From Death Sentence to Cure

Evolocumab Cuts Death Risk for a First Heart Attack or Stroke